Liang Wen-Chen, Ohkuma Aya, Hayashi Yukiko K, López Luis Carlos, Hirano Michio, Nonaka Ikuya, Noguchi Satoru, Chen Liang-Hui, Jong Yuh-Jyh, Nishino Ichizo
Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi-cho, Kodaira, Tokyo 187-8502, Japan.
Neuromuscul Disord. 2009 Mar;19(3):212-6. doi: 10.1016/j.nmd.2009.01.008. Epub 2009 Feb 26.
Multiple acyl-CoA dehydrogenase deficiency (MADD) is a metabolic disorder due to dysfunction of electron transfer flavoprotein (ETF) or ETF-ubiquinone oxidoreductase (ETF-QO). Mutations in ETFDH, encoding ETF-QO have been associated with both riboflavin-responsive and non-responsive MADD as well as a myopathic form of CoQ(10) deficiency, although pathomechanisms responsible for these different phenotypes are not well-defined. We performed mutation analysis in four Taiwanese MADD patients. Three novel ETFDH mutations were identified in four patients and all harbored the p.A84T mutation. Muscle CoQ(10) levels and respiratory chain activities measured in two patients were normal. Three patients improved on riboflavin together with carnitine. Our results show that not all MADD patients have CoQ(10) deficiency. Based upon our data, riboflavin and carnitine may be the first-line treatment for MADD.
多种酰基辅酶A脱氢酶缺乏症(MADD)是一种由于电子传递黄素蛋白(ETF)或ETF-泛醌氧化还原酶(ETF-QO)功能障碍引起的代谢紊乱。编码ETF-QO的ETFDH基因突变与核黄素反应性和非反应性MADD以及肌病形式的辅酶Q10缺乏有关,尽管导致这些不同表型的发病机制尚不清楚。我们对四名台湾MADD患者进行了突变分析。在四名患者中鉴定出三个新的ETFDH突变,并且都含有p.A84T突变。在两名患者中测量的肌肉辅酶Q10水平和呼吸链活性正常。三名患者使用核黄素和肉碱后病情改善。我们的结果表明,并非所有MADD患者都有辅酶Q10缺乏。根据我们的数据,核黄素和肉碱可能是MADD的一线治疗方法。